Market Overview:
The global CINV drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into aloxi, zofran generic, kytril generic, emend, akynzeo, sustol rolapitant. Aloxi held a dominant share in 2017 and is expected to maintain its dominance during the forecast period as well.
Product Definition:
CINV Existing and Pipeline Drugs are important because they help to prevent nausea and vomiting in people who are receiving chemotherapy or radiation therapy.
Aloxi:
Aloxi (alaproclate) is an oral drug that reduces the amount of acid produced by the stomach. It is used to treat heartburn, a common condition experienced by people who consume a high-acid diet. The medicine works by neutralizing or reducing the production of acid in the stomach and thus provides relief from indigestion and discomfort.
The global Aloxi market size was valued at USD 743 million in 2016.
Zofran Generic:
Zofran (Onfenberg) is a drug used to treat nausea and vomiting caused by cancer chemotherapy, radiation therapy, surgery, and disease-related nausea. Zofran’s generic name is Ondansetron. It was approved by the U.S FDA in 2009 as the first anti-nausea drug for cancer patients with no other effective therapies at that time.
Application Insights:
The global market is segmented by application into hospitals, specialty clinics, diagnostic centers, therapeutics and hospital pharmacies. Hospitals held the largest share of over 70% in 2017. This is due to factors such as presence of a large patient base with CINV symptoms and increasing prevalence of chronic diseases that require long-term treatment.
Chronic intestinal neurovascular disorders (CIND) are one of the most common conditions affecting older adults resulting in severe pain in the abdomen or chest along with other symptoms such as nausea and dizziness caused due to compression on internal organs including kidneys or arteries leading to emergency room visits or hospitalization. The rising geriatric population across the globe has increased awareness about this condition which may result in high demand for effective management solutions thereby driving growth during forecast years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors contributing to its growth. In addition, growing prevalence of CINV conditions such as asthma and epilepsy is expected to drive regional market growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising healthcare expenditure by governments along with an increase in awareness regarding chronic pain management among patients suffering from other diseases or injuries.
Growth Factors:
- Increasing incidence of cancer: The incidence of cancer is increasing at an alarming rate across the globe. This is primarily due to the changing lifestyle and dietary habits of people. As a result, there is a growing demand for effective treatments for cancer, including drugs for CINV.
- Growing awareness about CINV: There is growing awareness among patients and healthcare professionals about the symptoms and treatment options for CINV. This is helping to drive demand for CINV drugs in the market.
- Availability of new drug therapies: A number of new drug therapies are becoming available in the market that offer better efficacy and safety profiles than older drugs used for treating CINV. This is helping to boost growth prospects for the global CINV Existing and Pipeline Drugs market .
- . Rising prevalence of chemotherapy-induced nausea and vomiting: The prevalence of chemotherapy-induced nausea and vomiting (CINV) is rising due to increasing use of chemotherapy as a treatment modality across different types if cancers patients’ population base). As a result, there is an increase in demand from patients suffering from this condition, which in turn drives growth prospectsforC IN VExistingandPipelineDrugsmarket .
Scope Of The Report
Report Attributes
Report Details
Report Title
CINV Existing and Pipeline Drugs Market Research Report
By Type
Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL, Rolapitant
By Application
Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores
By Companies
GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, GlaxoSmithKline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
199
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global CINV Existing and Pipeline Drugs Market Report Segments:
The global CINV Existing and Pipeline Drugs market is segmented on the basis of:
Types
Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL, Rolapitant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Helsinn
- Heron Therapeutics
- Merck
- Tesaro
- GlaxoSmithKline
Highlights of The CINV Existing and Pipeline Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aloxi
- Zofran Generic
- Kytril Generic
- Emend
- Akynzeo
- SUSTOL
- Rolapitant
- By Application:
- Hospitals
- Specialty Clinics
- Diagnostic Centers Therapeutics
- Hospital Pharmacies
- Drugstores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CINV Existing and Pipeline Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CINV is an acronym for Clostridium Infections and Neoplasms. CINV refers to any infection or tumor caused by Clostridium bacteria. The term "pipeline drugs" refers to medications that are in development or have already been approved by the FDA for use in humans.
Some of the major players in the cinv existing and pipeline drugs market are GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, GlaxoSmithKline.
The cinv existing and pipeline drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CINV Existing and Pipeline Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CINV Existing and Pipeline Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CINV Existing and Pipeline Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CINV Existing and Pipeline Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CINV Existing and Pipeline Drugs Market Size & Forecast, 2020-2028
4.5.1 CINV Existing and Pipeline Drugs Market Size and Y-o-Y Growth
4.5.2 CINV Existing and Pipeline Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Aloxi
5.2.2 Zofran Generic
5.2.3 Kytril Generic
5.2.4 Emend
5.2.5 Akynzeo
5.2.6 SUSTOL
5.2.7 Rolapitant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Diagnostic Centers Therapeutics
6.2.4 Hospital Pharmacies
6.2.5 Drugstores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CINV Existing and Pipeline Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CINV Existing and Pipeline Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Aloxi
9.6.2 Zofran Generic
9.6.3 Kytril Generic
9.6.4 Emend
9.6.5 Akynzeo
9.6.6 SUSTOL
9.6.7 Rolapitant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.10.3 Diagnostic Centers Therapeutics
9.10.4 Hospital Pharmacies
9.10.5 Drugstores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Aloxi
10.6.2 Zofran Generic
10.6.3 Kytril Generic
10.6.4 Emend
10.6.5 Akynzeo
10.6.6 SUSTOL
10.6.7 Rolapitant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.10.3 Diagnostic Centers Therapeutics
10.10.4 Hospital Pharmacies
10.10.5 Drugstores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Aloxi
11.6.2 Zofran Generic
11.6.3 Kytril Generic
11.6.4 Emend
11.6.5 Akynzeo
11.6.6 SUSTOL
11.6.7 Rolapitant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.10.3 Diagnostic Centers Therapeutics
11.10.4 Hospital Pharmacies
11.10.5 Drugstores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Aloxi
12.6.2 Zofran Generic
12.6.3 Kytril Generic
12.6.4 Emend
12.6.5 Akynzeo
12.6.6 SUSTOL
12.6.7 Rolapitant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.10.3 Diagnostic Centers Therapeutics
12.10.4 Hospital Pharmacies
12.10.5 Drugstores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Aloxi
13.6.2 Zofran Generic
13.6.3 Kytril Generic
13.6.4 Emend
13.6.5 Akynzeo
13.6.6 SUSTOL
13.6.7 Rolapitant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.10.3 Diagnostic Centers Therapeutics
13.10.4 Hospital Pharmacies
13.10.5 Drugstores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CINV Existing and Pipeline Drugs Market: Competitive Dashboard
14.2 Global CINV Existing and Pipeline Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Helsinn
14.3.3 Heron Therapeutics
14.3.4 Merck
14.3.5 Tesaro
14.3.6 GlaxoSmithKline
